Trillium Therapeutics Company Profile (NASDAQ:TRIL)

About Trillium Therapeutics

Trillium Therapeutics logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TRIL
  • CUSIP:
Key Metrics:
  • Previous Close: $6.55
  • 50 Day Moving Average: $5.64
  • 200 Day Moving Average: $9.80
  • 52-Week Range: $4.50 - $17.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.11
  • P/E Growth: 0.00
  • Market Cap: $50.03M
  • Outstanding Shares: 7,817,000
  • Beta: 1
Profitability:
  • Return on Equity: -57.62%
  • Return on Assets: -30.72%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.72%
  • Quick Ratio: 11.72%
Additional Links:
Companies Related to Trillium Therapeutics:

Analyst Ratings

Consensus Ratings for Trillium Therapeutics (NASDAQ:TRIL) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.25 (304.17% upside)

Analysts' Ratings History for Trillium Therapeutics (NASDAQ:TRIL)
Show:
DateFirmActionRatingPrice TargetDetails
12/5/2016Cowen and CompanyReiterated RatingBuyView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyView Rating Details
11/3/2016Leerink SwannReiterated RatingOutperform$20.00View Rating Details
10/6/2016BTIG ResearchInitiated CoverageBuy$21.00View Rating Details
8/3/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$18.00View Rating Details
6/6/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$38.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Trillium Therapeutics (NASDAQ:TRIL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Trillium Therapeutics (NASDAQ:TRIL)
Current Year EPS Consensus Estimate: $-2.83 EPS
Next Year EPS Consensus Estimate: $-2.85 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.61)($0.61)($0.61)
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.81)($0.81)($0.81)
Q4 20161($0.91)($0.91)($0.91)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Trillium Therapeutics (NASDAQ:TRIL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Trillium Therapeutics (NASDAQ:TRIL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Trillium Therapeutics (NASDAQ:TRIL)
DateHeadline
finance.yahoo.com logoTrillium Therapeutics to Present at Investor and Scientific Conferences in February (NASDAQ:TRIL)
finance.yahoo.com - February 8 at 8:04 AM
streetinsider.com logoTrillium Therapeutics (TRIL) Outlines 2017 Anticipated Activities and Milestones (NASDAQ:TRIL)
www.streetinsider.com - February 3 at 6:19 AM
reuters.com logoBRIEF-Trillium Therapeutics Inc intends to provide an update on ongoing TTI-621 trials (NASDAQ:TRIL)
www.reuters.com - February 3 at 6:19 AM
finance.yahoo.com logoTrillium Therapeutics Outlines Anticipated Activities and Milestones for 2017 (NASDAQ:TRIL)
finance.yahoo.com - February 3 at 6:19 AM
finance.yahoo.com logo7:15 am Trillium Therapeutics outlines its expected 2017 activities and milestones (NASDAQ:TRIL)
finance.yahoo.com - February 3 at 6:19 AM
reuters.com logoBRIEF-Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial (NASDAQ:TRIL)
www.reuters.com - February 1 at 7:00 AM
streetinsider.com logoTrillium Therapeutics (TRIL) Initiates Dosing in Second Phase 1 Trial of TTI-621 (NASDAQ:TRIL)
www.streetinsider.com - February 1 at 7:00 AM
finance.yahoo.com logoTrillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial (NASDAQ:TRIL)
finance.yahoo.com - February 1 at 7:00 AM
4-traders.com logoTrillium Therapeutics : January 2017 Corporate Presentation (NASDAQ:TRIL)
www.4-traders.com - January 26 at 6:25 AM
News IconStock Volatility Review for Trillium Therapeutics Inc. (TSX:TR) - Gilbert Daily (NASDAQ:TRIL)
gilbertdaily.com - January 25 at 7:39 AM
News IconInvestors are Watching Technical Levels on Shares of Trillium Therapeutics Inc. (TRIL) - Sherwood Daily (NASDAQ:TRIL)
sherwooddaily.com - January 22 at 8:00 PM
News IconTrillium Therapeutics Inc TR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TRIL)
www.bioportfolio.com - January 20 at 7:13 AM
News IconTrillium Therapeutics Inc. (NASDAQ: TRIL) stock rating reiterated at Leerink Swann - BNB Daily (blog) (NASDAQ:TRIL)
www.baseball-news-blog.com - January 6 at 6:15 AM
investornewswire.com logoTrillium Therapeutics Inc. (NASDAQ:TRIL) Strong Buy Recommendations At 4 - Investor Newswire (NASDAQ:TRIL)
www.investornewswire.com - December 31 at 2:11 AM
News IconDaily Sentiment Score Of Trillium Therapeutics Inc. (NASDAQ:TRIL) At -0.217 - Stock Observer (NASDAQ:TRIL)
www.thestockobserver.com - December 29 at 8:16 PM
investornewswire.com logoTrillium Therapeutics Inc. (NASDAQ:TRIL) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:TRIL)
www.investornewswire.com - December 24 at 7:40 PM
News IconTrillium Therapeutics Inc. (NASDAQ:TRIL) Quarterly EPS Seen At $-0.89 - Stock Observer (NASDAQ:TRIL)
www.thestockobserver.com - December 14 at 6:40 AM
News IconMarket Review: Indicator Watch for Trillium Therapeutics Inc. (TRIL) - Yankee Analysts (NASDAQ:TRIL)
yankeeanalysts.com - December 14 at 6:40 AM
News IconTrillium Therapeutics Inc. (NASDAQ:TRIL) Bearish Target At $20 - Stock Observer (NASDAQ:TRIL)
www.thestockobserver.com - December 11 at 8:31 AM
News IconInside Track: Trading Focus on Shares of Trillium Therapeutics Inc. (TRIL) - Yankee Analysts (NASDAQ:TRIL)
yankeeanalysts.com - December 11 at 8:31 AM
News IconWhat are the Levels Indicating for This Stock: Trillium Therapeutics Inc. (TRIL) - Yankee Analysts (NASDAQ:TRIL)
yankeeanalysts.com - December 8 at 1:11 AM
News IconBrokers Add To Their Ratings On Trillium Therapeutics Inc. (TRIL) - NewsDen (NASDAQ:TRIL)
newsden.net - December 7 at 8:01 AM
News IconTrillium Therapeutics Inc. (NASDAQ:TRIL) Quarterly EPS Seen At ... - Stock Observer (NASDAQ:TRIL)
www.thestockobserver.com - December 6 at 7:54 PM
News IconPenny Stock Worth Watching: Trillium Therapeutics Inc (TR) Declined -1.54% on Dec 6 - Herald KS (NASDAQ:TRIL)
heraldks.com - December 6 at 7:54 PM
capitalcube.com logoTrillium Therapeutics, Inc. :TRIL-US: Earnings Analysis: Q3, 2016 By the Numbers : December 6, 2016 (NASDAQ:TRIL)
www.capitalcube.com - December 6 at 7:54 PM
News IconTop Gainer of the Day: Trillium Therapeutics Inc. (NASDAQ:TRIL) - Prospect Journal (NASDAQ:TRIL)
prospectjournal.com - December 6 at 8:18 AM
News IconReady for a Breakout? Stock Update on Trillium Therapeutics Inc. (TRIL) - Yankee Analysts (NASDAQ:TRIL)
yankeeanalysts.com - December 6 at 8:18 AM
streetinsider.com logoTrillium Therapeutics (TRIL) Announces Presentation of Initial TTI-621 Data in AMMs (NASDAQ:TRIL)
www.streetinsider.com - December 5 at 8:37 AM
us.rd.yahoo.com logo1:46 am Trillium Therapeutics presents initial data from ongoing study of TTI-621; believes data from this study provide preliminary evidence that TTI-621 monotherapy is both active and well tolerated (NASDAQ:TRIL)
us.rd.yahoo.com - December 5 at 8:37 AM
einnews.com logoTeen struck by lightning in storm (NASDAQ:TRIL)
semiconductors.einnews.com - December 4 at 8:30 AM
einnews.com logoBigg Boss 10 December 3 highlights: Mona Lisa's boyfriend says her closeness to Manu is just an acting (NASDAQ:TRIL)
ethanol.einnews.com - December 4 at 8:30 AM
finance.yahoo.com logoTrillium Presents Initial Data From Ongoing Study of … (NASDAQ:TRIL)
finance.yahoo.com - December 4 at 8:30 AM
finance.yahoo.com logoTrillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting (NASDAQ:TRIL)
finance.yahoo.com - December 3 at 7:12 PM
News IconTrillium Therapeutics, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 (NASDAQ:TRIL)
www.bioportfolio.com - November 28 at 8:57 AM
News IconStock Value Diminishing over Past Month: Trillium Therapeutics Inc. (NASDAQ:TRIL) - CSZ News (NASDAQ:TRIL)
cincysportszone.com - November 26 at 9:12 AM
News IconTracking the Numbers for Trillium Therapeutics Inc. (TSX:TR) - Stock Newsweek (NASDAQ:TRIL)
stocknewsweek.com - November 23 at 8:09 PM
News IconTechnical Investors are Checking in on Shares of Trillium Therapeutics Inc. (TRIL) - MicroCap Wired (NASDAQ:TRIL)
www.microcapwired.com - November 23 at 8:09 PM
News IconTrillium Therapeutics (TRIL) – Analysts' Recent Ratings Updates - Digital Cameras Planet Blog (blog) (NASDAQ:TRIL)
digital-cameras-planet.com - November 22 at 8:06 PM
News IconReviewing Indicator Levels for Trillium Therapeutics Inc. (TRIL) - Yankee Analysts (NASDAQ:TRIL)
yankeeanalysts.com - November 22 at 8:06 PM
News IconTechnical Focus: Williams %R, ADX, and CCI Levels for Trillium Therapeutics Inc. (TRIL) - MicroCap Wired (NASDAQ:TRIL)
www.microcapwired.com - November 21 at 8:31 PM
News IconInvestors are Watching Shares of Trillium Therapeutics Inc. (TSX:TR ... - Stock Newsweek (NASDAQ:TRIL)
stocknewsweek.com - November 21 at 9:17 AM
News IconFollowing the Charts on Shares of Trillium Therapeutics Inc. (TRIL) - MicroCap Wired (NASDAQ:TRIL)
www.microcapwired.com - November 21 at 9:17 AM
News IconTrillium Therapeutics Inc. TR Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:TRIL)
www.bioportfolio.com - November 20 at 7:34 PM
News IconTrillium Therapeutics Inc. (NASDAQ:TRIL) Profit Seen At $-0.89 - Stock Observer (NASDAQ:TRIL)
www.thestockobserver.com - November 19 at 7:49 PM
News IconTrillium Therapeutics Inc. TR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:TRIL)
www.bioportfolio.com - November 18 at 7:35 PM
News IconIndicator Level Review for Trillium Therapeutics Inc. (TRIL) - Yankee Analysts (NASDAQ:TRIL)
yankeeanalysts.com - November 18 at 11:26 AM
News IconRange Watch on Technical Indicators for Trillium Therapeutics Inc. (TRIL) - MicroCap Wired (NASDAQ:TRIL)
www.microcapwired.com - November 15 at 11:45 AM
News IconMA Watch on Shares of Trillium Therapeutics Inc. (TRIL) - MicroCap Wired (NASDAQ:TRIL)
www.microcapwired.com - November 10 at 7:59 PM
News IconWatching the Numbers for Trillium Therapeutics Inc. (TSX:TR) - Stock Newsweek (NASDAQ:TRIL)
stocknewsweek.com - November 10 at 11:34 AM
News IconShares Knocked Down Over Past Month: Trillium Therapeutics Inc. (NASDAQ:TRIL) - CSZ News (NASDAQ:TRIL)
cincysportszone.com - November 5 at 7:40 PM

Social

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Where is Trillium Therapeutics' stock going? Where will Trillium Therapeutics' stock price be in 2017?

6 equities research analysts have issued 1 year price objectives for Trillium Therapeutics' shares. Their forecasts range from $18.00 to $38.00. On average, they expect Trillium Therapeutics' share price to reach $24.25 in the next year.

What are analysts saying about Trillium Therapeutics stock?

Here are some recent quotes from research analysts about Trillium Therapeutics stock:

  • According to Zacks Investment Research, "Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. " (2/9/2017)

  • Cowen and Company analysts commented, "The key investor concern coming into ASH was safety of the 0.2mg/kg/week dose of." (12/5/2016)

  • Ladenburg Thalmann Financial Services analysts commented, "an attractive investment opportunity in the immuno-oncology space with substantial upside potential and multiple downside protection."Further, the target price of $18 represents a potential upside of 95 percent over Tuesday's close of $9.21.Toronto-based Trillium is an immuno-oncology-focused company developing innovative therapies for cancer. Its lead program, TTI-621, is a antibody-like fusion protein targeting CD47, the blockade of which is shown to have improved anti-tumor phagocytosis and innate immunity. "We expect TTI-621 to likely show better safety, higher potency and/or more favorable PK profile than the other lead competitors, and have best-in-class potential," analyst Wangzhi Li said.Related Link: Biogen, Ionis Reveal Nusinersen Meets Primary Endpoint At Interim Analysis Of Final Stage ENDEAR TrialLi noted that the current market values Trillium at about $45 million–$95 million, exclusive of its current cash (about $45 million). In fact, the analyst said the upfront payments alone were over $200 million for the co-development/promotion partnership rights to a number of similar immune-oncology programs at preclinical or Phase 1 stage.Li sees escalation in partnership interest with Trillium if TTI-621 shows positive results in Phase 1 study.The analyst noted that there is multiple downside protection to the stock in the form of sufficient cash balance, CD200 mAb platform, fluorine-based medicinal chemistry platform and a pipeline of small molecules directed at immuno-oncology targets."Our modeling indicates the downside valuation of TRIL is protected at over $50 million, or over $4.70 per diluted share, even in the potential scenario of writing off the TT1-621 program," (8/3/2016)

Who owns Trillium Therapeutics stock?

Trillium Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Capital Management LLC (7.31%), Franklin Resources Inc. (5.05%), Opaleye Management Inc. (1.41%), New Leaf Venture Partners L.L.C. (1.24%) and Oxford Asset Management (0.32%).

Who sold Trillium Therapeutics stock? Who is selling Trillium Therapeutics stock?

Trillium Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc..

Who bought Trillium Therapeutics stock? Who is buying Trillium Therapeutics stock?

Trillium Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Oxford Asset Management and Janus Capital Management LLC.

How do I buy Trillium Therapeutics stock?

Shares of Trillium Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Trillium Therapeutics stock cost?

One share of Trillium Therapeutics stock can currently be purchased for approximately $6.00.

Trillium Therapeutics (NASDAQ:TRIL) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Earnings History Chart

Earnings by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Dividend History Chart

Dividend Payments by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Last Updated on 2/22/2017 by MarketBeat.com Staff